Synapse - Find an Expert

115370 Results

Risk factors of smoldering multiple myeloma: Results from the screened iStopMM study

Meeting Abstract

Thorsteinsdottir, S.; Sverrisdottir, I.; Rögnvaldsson, S.; Ekberg, S.; Hultcrantz, M.; Vidarsson, B.; Onundarson, P. T.; Agnarsson, B.; Sigurdardottir, M.; Thorsteinsdottir, I.; more...
Blood (2023)

Fulltext@MSK | Save

Pre-treatment pulmonary assessment have limited utility in B-cell lymphoma patients treated with autologous anti-CD19 CAR T-cell therapy

Meeting Abstract

Sdayoor, I.; Shouval, R.; Fried, S.; Marcus, R.; Danylesko, I.; Yerushalmi, R.; Shem-Tov, N.; Itzhaki, O.; Jacoby, E.; Kedmi, M.; more...
Blood (2023)

Fulltext@MSK | Save

Takeaim lymphoma: An open-label, dose escalation and expansion trial of emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies

Meeting Abstract

Grommes, C.; Tun, H.; Rosenthal, A. C.; Lunning, M. A.; Ramchandren, R.; Regales, L.; Zhao, W.; Lane, M.; Wang, C.; von Roemeling, R.; more...
Blood (2023)

Fulltext@MSK | Save

Cost per responder analysis of patients with lenalidomide-refractory multiple myeloma who received cilta-cel from the CARTITUDE-4 Trial

Meeting Abstract

Hansen, D. K.; Lu, X.; Castaneda, O.; Sorensen, S.; Usmani, S. Z.; Zhang, E.; Huo, S.; Jagannath, S.
Blood (2023)

Fulltext@MSK | Save

Fixed-duration pirtobrutinib combined with venetoclax ± rituximab in relapsed/refractory chronic lymphocytic leukemia: Updated results, including MRD data, from the BRUIN phase 1b study

Meeting Abstract

Roeker, L. E.; Woyach, J. A.; Cheah, C. Y.; Coombs, C. C.; Shah, N. N.; Wierda, W. G.; Patel, M.; Tsai, D. E.; Nair, B.; Wang, C.; more...
Blood (2023)

Fulltext@MSK | Save

The value of collaboration with patient advocacy organizations to enhance initiatives focused on patient-centered care and improve outcomes in chronic lymphocytic leukemia

Meeting Abstract

Deluca, C.; Beyer, M.; Drew, H.; Murray, J.; Massey, J.; Koffman, B.; Battiato, K.; Gribben, J. G.; Lamanna, N.; Russomanno, C.
Blood (2023)

Fulltext@MSK | Save

A global, phase 3, randomized, double-blind study to evaluate safety and efficacy of selinexor, an XPO-1 inhibitor, in combination with ruxolitinib in JAK inhibitor-naïve myelofibrosis (XPORT-MF-034)

Meeting Abstract

Maher, K.; Rampal, R. K.; Bose, P.; Podoltsev, N. A.; Harrison, C. N.; Hong, J.; Wang, X.; Chamoun, K.; Mascarenhas, J.
Blood (2023)

Fulltext@MSK | Save

Final results of a phase I/II trial of carfilzomib + R-CHOP for frontline treatment of patients with non-germinal center diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Hill, B. T.; Torka, P.; Hernandez-Ilizaliturri, F. J.; Dean, R. M.; Jagadeesh, D.; Karamlou, K.; Fu, C. L.; Winter, A.; Krauspe, E.; Zhou, J.; more...
Blood (2023)

Fulltext@MSK | Save

SARS-CoV-2 infection does not lead to progression of monoclonal gammopathy of undetermined significance: Results from the population-based iStopMM screening study